Donepezil Hydrochloride
Product Images NDC 54868-6207

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 54868-6207). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of 10 mg Package Label (6207)

Label for Donepezil Hydrochloride 10 mg tablets from Physicians Total Care, Inc. The label shows the NDC number 54868-6207-0, lot number, and expiration date. It indicates a quantity of 90 tablets and includes a barcode for scanning.*

FDA Label Image

Image Of 5 mg Package Label (6208)

Packaging label for Donepezil Hydrochloride 5 mg tablets, distributed by Physicians Total Care, Inc. The label shows the lot number, expiration date (01/60), and a barcode. The package contains 30 tablets.*

FDA Label Image

Image Of Chemical Structure (Chemical Structure)

Chemical structure of Donepezil Hydrochloride, showing the molecular arrangement of its atoms including aromatic rings, ether groups, and a piperidine ring, associated with a hydrochloride (HCl) molecule.*

FDA Label Image

Image Of Figure 1 (Figure01)

A line graph showing the time-course of change from baseline in ADAS-cog scores over 24 weeks for patients receiving placebo, 5 mg/day, and 10 mg/day drug treatments. The y-axis measures mean change with clinical improvement and decline labeled. The x-axis measures weeks of drug treatment. Data points show trends for each treatment group with error bars.*

FDA Label Image

Image Of Figure 2 (Figure02)

A line graph showing the cumulative percentage of patients completing 24 weeks of double-blind treatment with Donepezil Hydrochloride at 5 mg and 10 mg doses compared to placebo. The graph depicts changes from baseline ADAS-cog scores, with data points for placebo, 5 mg/day, and 10 mg/day groups, showing treatment effects over a range of score changes.*

FDA Label Image

Image Of Figure 3 (Figure03)

A bar graph showing the frequency distribution of CIBIC plus scores at Week 24. The x-axis lists categories ranging from 'Markedly Improved' to 'Markedly Worse,' and the y-axis shows the percentage of patients. Three groups are compared: Placebo, 5 mg/day, and 10 mg/day, with different bar colors representing each group.*

FDA Label Image

Image Of Figure 4 (Figure04)

A line graph showing the time-course of change from baseline in ADAS-cog scores for patients completing a 15-week drug treatment trial with placebo, 5 mg/day, and 10 mg/day doses of donepezil hydrochloride. The x-axis represents weeks of drug treatment, and the y-axis indicates mean change with clinical improvement and decline marked.*

FDA Label Image

Image Of Figure 5 (Figure05)

A line graph showing the cumulative percentage of patients with specified changes from baseline ADAS-cog scores for three groups: Placebo, Donepezil 5 mg, and Donepezil 10 mg. The x-axis represents change from baseline, and the y-axis represents the cumulative percentage of patients. Data illustrates treatment group comparisons across different improvement thresholds.*

FDA Label Image

Image Of Figure 6 (Figure06)

A bar chart showing the frequency distribution of CIBIC plus scores at Week 12. The x-axis categorizes patient responses from markedly improved to markedly worse, while the y-axis represents the percentage of patients. Data are compared across placebo, 5 mg/day, and 10 mg/day groups, illustrated by different colored bars.*

FDA Label Image

Image Of Figure 7 (Figure07)

A line graph showing the mean change from baseline in SIB score over 6 months for Donepezil 10 mg/day versus placebo. The vertical axis represents mean change with standard error, while the horizontal axis represents time in months. Donepezil shows clinical improvement above baseline, whereas placebo shows clinical decline.*

FDA Label Image

Image Of Figure 8 (Figure08)

A cumulative percentage chart showing patients completing 6 months of double-blind treatment. The x-axis represents change from baseline in SIB scores, and the y-axis is the cumulative percentage of patients. It compares Donepezil 10 mg/day (black circles) with placebo (gray squares), illustrating particular changes from baseline with a vertical reference line at zero.*

FDA Label Image

Image Of Figure 9 (Figure09)

A line graph depicting the mean change from baseline in ADCS-ADL scores over 6 months for patients treated with Donepezil 10 mg/day versus placebo. The x-axis represents months, and the y-axis shows the mean change with standard error. The graph indicates clinical improvement or decline relative to baseline.*

FDA Label Image

Image Of Figure 10 (Figure10)

A cumulative percentage line graph comparing patients treated with Donepezil 10 mg/day versus placebo. The x-axis shows change from baseline, and the y-axis shows cumulative percentage of patients, illustrating patient responses over a 6-month double-blind treatment period.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.